Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors
Small · 2024-05 · 20 (19)
DOI: 10.1002/smll.202308731 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 07.02.2024. Verfasst von Zi-Zhan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Lab…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Nanoparticles, Lymph Nodes. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 212 Literaturangaben. Gefördert von: Postdoctoral Science Foundation of China, Hubei Province Chinese Medicine Research Project, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Immunotherapy has emerged as a potent strategy in cancer treatment, with many approved drugs and modalities in the development stages. Despite its promise, immunotherapy is not without its limitations, including side effects and suboptimal efficacy. Using nanoparticles (NPs) as delivery vehicles to target immunotherapy to lymph nodes (LNs) can improve the efficacy of immunotherapy drugs and reduce side effects in patients. In this context, this paper reviews the development of LN‐targeted immunotherapeutic NP strategies, the mechanisms of NP transport during LN targeting, and their related biosafety risks. NP targeting of LNs involves either passive targeting, influenced by NP physical properties, or active targeting, facilitated by affinity ligands on NP surfaces, while alternative methods, such as intranodal injection and high endothelial venule (HEV) targeting, have uncertain clinical applicability and require further research and validation. LN targeting of NPs for immunotherapy can reduce side effects and increase biocompatibility, but risks such as toxicity, organ accumulation, and oxidative stress remain, although strategies such as biodegradable biomacromolecules, polyethylene glycol (PEG) coating, and impurity addition can mitigate these risks. Additionally, this work concludes with a future‐oriented discussion, offering critical insights into the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan Univer…
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, Department of Oral & Maxillofacial - Head Neck…
- School of Dentistry, The University of Queensland, 288 Herston Road, Brisbane, 4066, Australia.
ORCID-Profile: Zi-Zhan Li, Nian-Nian Zhong, Lin-Lin Bu
Förderung
- Postdoctoral Science Foundation of China
- Hubei Province Chinese Medicine Research Project
- Natural Science Foundation of Hubei Province
- Medical Young Talents Program of Hubei Province
- Wuhan Young Medical Talents Training Project
Zitieren
APA
Li, Z. Z., Zhong, N. N., Cao, L. M., Cai, Z. M., Xiao, Y., Wang, G. R., Liu, B., Xu, C., & Bu, L. L. (2024). Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors. Small, 20(19). https://doi.org/10.1002/smll.202308731
Vancouver
Li ZZ, Zhong NN, Cao LM, Cai ZM, Xiao Y, Wang GR, et al. Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors. Small. 2024;20(19). doi:10.1002/smll.202308731
BibTeX
@article{Li2024,
author = {Li, Zi-Zhan and Zhong, Nian-Nian and Cao, Lei-Ming and Cai, Ze-Min and Xiao, Yao and Wang, Guang-Rui and Liu, Bing and Xu, Chun and Bu, Lin-Lin},
title = {Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors},
journal = {Small},
year = {2024},
volume = {20},
number = {19},
doi = {10.1002/smll.202308731}
}
EUVIMED